Among those agents combined with FLT3‐TKIs, BCL2 inhibitor venetoclax exhibited strong synergistic effects on inhibiting the proliferation of FLT3‐ITD–positive cells and re‐sensitized FLT3‐TKI–resistant cells; BRD4 inhibitor JQ1 had synergistic lethal effects in AML and could help overcome FLT3‐TKI resistance; HHT could help to inhibit the growth of drug‐resistant clones and increase the antileukemia effects in FLT3‐ITD AML [28, 29, 30]. This evidence concerns the gene BRD4 and acute myeloid leukemia.